Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 15 of 9001 results

  1. Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors (review of TA881) [ID6496]

    In development Reference number: GID-TA11676 Expected publication date:  28 April 2026

    Technology appraisal guidance
    In development

  2. Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over [ID6407]

    In development Reference number: GID-TA11498 Expected publication date:  29 April 2026

    Technology appraisal guidance
    In development

  3. Sodium zirconium cyclosilicate for treating hyperkalaemia (partial review of TA599) [ID6439]

    In development Reference number: GID-TA11561 Expected publication date:  29 April 2026

    Technology appraisal guidance
    In development

  4. Belantamab mafodotin with bortezomib and dexamethasone for previously treated multiple myeloma [ID6212]

    In development Reference number: GID-TA11203 Expected publication date:  30 April 2026

    Technology appraisal guidance
    In development

  5. Digital technologies to support self-management of asthma: early value assessment

    In development Reference number: GID-HTE10063 Expected publication date:  05 May 2026

    Health technology evaluations
    In development

  6. Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177]

    In development Reference number: GID-TA11140 Expected publication date:  06 May 2026

    Technology appraisal guidance
    In development

  7. Ectopic pregnancy and miscarriage

    In development Reference number: GID-QS10202 Expected publication date:  06 May 2026

    Quality standard
    In development

  8. Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 therapies (MA review TA704 and TA862) [ID5121]

    In development Reference number: GID-TA11674 Expected publication date:  07 May 2026

    Technology appraisal guidance
    In development

  9. Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more lines of systemic treatment [ID6388]

    In development Reference number: GID-TA11468 Expected publication date:  07 May 2026

    Technology appraisal guidance
    In development

  10. Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6442]

    In development Reference number: GID-TA11424 Expected publication date:  07 May 2026

    Technology appraisal guidance
    In development

  11. Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity [ID6441]

    In development Reference number: GID-TA11544 Expected publication date:  07 May 2026

    Technology appraisal guidance
    In development

  12. Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable [ID3843]

    In development Reference number: GID-TA10726 Expected publication date:  13 May 2026

    Technology appraisal guidance
    In development

  13. Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable [ID6249]

    In development Reference number: GID-TA11254 Expected publication date:  13 May 2026

    Technology appraisal guidance
    In development

  14. Neonatal infection: antibiotics for prevention and treatment - update

    In development Reference number: GID-NG10456 Expected publication date:  13 May 2026

    NICE guideline
    In development

  15. Suspected neurological conditions: recognition and referral (NG127)

    This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.

    NICE guideline
    Last updated
    2 October 2023

    Sections for NG127